Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.
about
Chimeric antigen receptor therapy for cancerGenetically modified T cells in cancer therapy: opportunities and challengesCAR therapy: the CD19 paradigm4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignanciesInduction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.Biology and clinical application of CAR T cells for B cell malignanciesThe basic principles of chimeric antigen receptor design.An oxygen sensitive self-decision making engineered CAR T-cell.Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.Genetically engineered T cells for the treatment of cancer.The promise and potential pitfalls of chimeric antigen receptors.Targeting tumours with genetically enhanced T lymphocytes.Engineering T cells for cancer therapy.Supernatural T cells: genetic modification of T cells for cancer therapy.Improving T cell therapy for cancer.A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.Immunotherapy of neuroblastoma: present, past and future.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsCAR-T Cell Therapy for Lymphoma.Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylationComplexity of anti-immunosenescence strategies in humans.Disialoganglioside directed immunotherapy of neuroblastoma.Immunology and immunotherapy of neuroblastomaSecond-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation.Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.Treatment of lymphoma with adoptively transferred T cells.Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivoCD19-CAR trials.Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.Adoptive immunotherapy for cancer.Advances in chimeric antigen receptor immunotherapy for neuroblastoma.Current status of chimeric antigen receptor therapy for haematological malignancies.CAR T-cell immunotherapy: The path from the by-road to the freeway?Chimeric antigen receptors: driving immunology towards synthetic biology.CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection.Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.
P2860
Q27013599-4C3907AE-0384-45A9-AC61-F8DC9D72CE3CQ27026627-5D2025B2-3084-4CCF-8853-AA3EDAA89682Q28081642-CD555130-A4A1-4E51-99CC-7BBC944D2C94Q33819935-9A5CAD6B-F820-40D4-A2D5-5C8C46F63703Q33896804-A11EED7D-371E-41FE-9B15-B09AD5DB056FQ33907565-2FBD4431-F232-4C9C-B5A1-62FAB05C30A5Q34036213-BA69398B-6647-4CC3-B5F2-B26CA9E1155EQ34047851-701CD5F5-2C8F-4336-9496-B3F9F47EB4DBQ34389202-66C00692-F52E-4E84-B89E-2DE660ED0F63Q34645898-197E35F5-2FBC-473C-8F76-AAD53C7CBA63Q34970378-43735F3E-CC26-4B71-B563-836B72C3FE22Q35037678-07E2A524-ADAD-4CBE-BB2B-5220650B2D71Q36298319-66D3C177-B33A-445E-8198-125B5178522FQ36328805-A497FFD8-E39E-4175-9848-1CBCC93BA58FQ36407236-EE996760-8F8B-42FF-B279-D2C1DADE7D60Q36413053-5E18A7BA-A288-4170-B835-2780249F7232Q36453273-FF4FD810-BB82-4BFA-8E8D-B31D7CC5F111Q36470354-86884390-6E96-45E5-9FBA-B3C4E8F4F005Q36519358-3D82D806-6313-4155-B4EA-B45F3F25B469Q36562605-F5B933D2-581F-447C-8032-5E885184C1F9Q36616598-7FD07C37-EDFB-4E8C-9DDB-224488C7EB92Q36761416-A8B32CB0-BFE4-484A-87A8-B84E19679B45Q36856798-72B6DACE-60EA-4D26-A2C9-58CF73AE054FQ37137406-AAE1F59F-FB5C-476E-A480-32C5D28F6B49Q37257207-1B9E5590-3F85-4D97-B85F-15DF59E5ECF8Q37419728-C66D2AE5-E823-4E67-BE86-B3E380FA8965Q37436837-19164673-6D29-45DA-A13D-4C578A39F632Q37692134-F595DAD9-8642-4D71-BE5D-A9698B12A8D8Q37751873-6F991DFE-C2BA-4E01-9FCD-135D75DD2FA0Q37785538-42E983D2-9D5B-4BE1-B4BB-AB6AD2E9F91AQ38170496-1294ED10-6E96-44C7-90F3-E485B35317C1Q38170885-378754C5-A877-4E51-B8FF-C25B822221EDQ38631108-9A8C7D35-5406-42D2-95BB-C595A03D9B36Q38632105-8C55EFFF-1C08-4414-B2DD-026A7519B495Q38884383-A23DF450-D04D-45FB-AD29-35243C5FC2DFQ39032901-080BD992-69BD-4038-9FF0-DEEDDB383BA1Q39062014-AFB9182F-6E20-48FF-93E9-784680D37D43Q39111432-60E6FACC-3CE4-4D33-B63F-8D434CBF822FQ39272183-3AC81673-A6DA-4E5D-A56C-A7F63F744406Q39360350-44D8CEB8-F281-4092-AC17-D8C514846DA7
P2860
Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Antigen-dependent CD28 signali ...... d human primary T lymphocytes.
@ast
Antigen-dependent CD28 signali ...... d human primary T lymphocytes.
@en
type
label
Antigen-dependent CD28 signali ...... d human primary T lymphocytes.
@ast
Antigen-dependent CD28 signali ...... d human primary T lymphocytes.
@en
prefLabel
Antigen-dependent CD28 signali ...... d human primary T lymphocytes.
@ast
Antigen-dependent CD28 signali ...... d human primary T lymphocytes.
@en
P2093
P2860
P356
P1476
Antigen-dependent CD28 signali ...... d human primary T lymphocytes.
@en
P2093
P2860
P304
P356
10.1084/JEM.188.4.619
P407
P577
1998-08-01T00:00:00Z